Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/19/2020 1:51:15 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:29:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:28:09 PM Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 4:38:29 PM Current Report Filing (8-k) Edgar (US Regulatory) - 5 RGLS Split History Regulus Therapeutics (RGLS) has 1 split in our RGLS split history database. The split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. RGLS | Regulus Therapeutics Inc. Insider Actions | MarketWatch
Regulus Therapeutics Inc. (RGLS) Stock Message Board ...
Regulus Therapeutics Inc. Common Stock (RGLS) Stock Quotes ... Regulus Therapeutics Inc. Common Stock (RGLS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. RGLS Regulus Therapeutics Inc. Stock Quote Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares GuruFocus.com Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States and Europe.
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/19/2020 1:51:15 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:29:00 PM Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/18/2020 4:28:09 PM Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2020 4:38:29 PM Current Report Filing (8-k) Edgar (US Regulatory) - 5
Guardion Health Sciences Inc, GHSI 0.48 0.02 (3.10%). NASDAQ Updated Jun 8, 2020 11:58 PM Remark Media. MARK 2.60 0.02 (0.76%). NASDAQ Updated Jun 9, 2020 8:01 AM Amneal Pharmaceuticals Inc. AMRX 4.95 0.00 (0.07%). NASDAQ Updated Jun 8, 2020 8:52 PM
Real-time trade and investing ideas on Regulus Therapeutics Inc. RGLS from the largest community of traders and investors.
Remark Media. MARK 2.60 0.02 (0.76%). NASDAQ Updated Jun 9, 2020 8:01 AM RGLS Stock Price, Forecast & News (Regulus Therapeutics) Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.13.
RGLS | Complete Regulus Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Learn about RGLS with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to Morningstar Premium to unlock our take on RGLS. Regulus Therapeutics (RGLS) Reports Earnings on Aug 13 Regulus Therapeutics (RGLS) reports earnings on 8/13/2020. Shares are up 33.2% since reporting last quarter. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Pre-Market Most Active for Nov 6, 2018 : AMD, RGLS, SQQQ ...